Dialectic Therapeutics, Inc., kambani yeTexas-based clinical stage biotechnology yakatarisana nekugadzira matekinoroji matsva ekurapa cancer, nhasi yazivisa kuti US Food and Drug Administration (FDA) yakapa nherera zita remushonga kuDT2216 kurapwa kweT-cell. lymphoma. DT2216 ndiyo yekutanga chizvarwa cheDialectic chivakwa chakavakwa chichishandisa proprietary uye novel Antiapoptotic Protein Targeted Degradation (APTaD™) tekinoroji chikuva.
"Ichi chiitiko chakakosha mukuvandudzwa kweDT2216, yedu inotungamira APTaD ™ komboni. Sarudzo yeFDA yekupa nherera zita remishonga inosimbisa kutenda kwedu kuti DT2216 inogona kuva mushonga unovimbisa kuvarwere veT-cell lymphoma” akadaro Dr. David Genecov, Mutungamiriri weDialectic uye Chief Executive Officer. "Pane kudiwa kwakakosha kusingagoneki kwevanhu vanobatwa negomarara iri risingawanzo, umo marapirwo azvino anotenderwa ane mwero wakaderera wekupindura".
Normal T-masero anoda BCL-XL kutaura kuti urarame thymic kusarudzwa panguva yekukura kwavo. Mushure mekusarudza thymic BCL-XL yakajairika T-masero haachatauri BCL-XL. Nekudaro, mazhinji T-cell lymphomas anoburitsa zvakare BCL-XL senzira yekuchinja kwavo neoplastic uye inobvumidza kuenderera kwavo kurarama sechirwere chinouraya. Zvidzidzo zvakaratidza kukosha kweBCL-XL muT-cell lymphoma kupona. Dialectic yakaratidza kuti DT2216 mushonga unoshanda weT-cell lymphoma muzvidzidzo zvepreclinical.
Hofisi yeFDA yeOrphan Products Development inopa chinzvimbo chenherera kumishonga uye biologics izvo zvakagadzirirwa kurapwa kwakachengeteka uye kunoshanda, kuongororwa kana kudzivirira zvirwere zvisingawanzo, kana mamiriro anobata vanhu vasingasviki zviuru mazana maviri muUS Orphan dhizaini inopa mamwe mabhenefiti, kusanganisira kurudziro yemari yekutsigira budiriro yekiriniki uye mukana weanosvika makore manomwe ekusarudzika pamusika muUS kana wabvumidzwa.